CSL Limited (CSL:ASX) の戦略的SWOT、PESTILE分析、財政インサイト

当レポートはオーストラリアの生物学的製剤専門のバイオテクノロジー企業、CSL Limitedを調査・分析した、Quaintel Researchの企業調査レポートです。

Report Summary

CSL Limited (CSL:ASX) Strategic SWOT, PESTLE Analysis and Financial Insights – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of CSL Limited’s business operations. It provides a detailed analysis of the company’s financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about CSL Limited, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses CSL Limited’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company’s operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of CSL Limited’s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers CSL Limited’s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares CSL Limited’s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors’ operations.

Finally, the report includes recent news and deal activities undertaken by CSL Limited, enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

CSL Limited operates as a biotechnology company that researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccine products. CSL Limited operates in three main business segments: CSL Behring for plasma products, CSL Seqirus for influenza vaccines, and CSL Vifor for nephrology products. CSL Limited offers plasma products to treat bleeding disorders, immunodeficiencies, hereditary angioedema, and alpha-1 antitrypsin deficiency. It provides vaccines to prevent influenza. CSL also offers products for iron deficiency, dialysis, and chronic kidney diseases. The company develops gene therapies and recombinant proteins as well. Founded in 1916, the company is headquartered in Melbourne, Victoria, Australia.

CSL Limited in the News:-

– 14-Feb-2025 – European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine
– 13-Feb-2025 – European Commission Approves CSL’s ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
– 07-Feb-2025 – CSL Behring’s Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
– 24-Jan-2025 – Australia’s Therapeutic Goods Administration (TGA) Approves Registration of CSL’s ANDEMBRY (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks
– 13-Dec-2024 – CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a company’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the company’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company’s future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the company’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the CSL Limited’s internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company CSL Limited:
• CSL Limited Porter’s Five Forces Analysis
• CSL Limited VRIO Analysis
• CSL Limited BCG Analysis
• CSL Limited Segmentation, Targeting and Positioning (STP) Analysis
• CSL Limited Ansoff Matrix Analysis

Table of Contents

COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
CSL Limited – Key Company Facts 8
CSL Limited – Company Description 9
CSL Limited – Top Executives 10
CSL Limited- Head Office & Locations 12
Head Office – Country 12
CSL Limited – Products and Services 13
Products 13
Services 16
CSL Limited – Company’s Mission and Vision 18
Mission 18
Vision 18
CSL Limited – Corporate Strategy 19
CSL Limited – Business Description 26
CSL Behring 27
CSL Seqirus 28
CSL Vifor 29
CSL Limited – ESG Spotlight 31
Environment 31
Social 32
Corporate Governance 33
CSL Limited – SWOT Analysis 34
Overview 34
Strengths 36
Weaknesses 40
Opportunities 41
Threats 43
CSL Limited – PESTLE Analysis 44
Overview 44
Political Factors 46
Economic Factors 48
Social Factors 50
Technological Factors 51
Legal Factors 52
Environmental Factors 54
CSL Limited – Financial Deep Dive 56
Share Price Trend – Feb-2024 to Feb-2025 (Average Share Closing Price) 56
Profit and Loss Statement 58
Summary of Profit and Loss Statement 58
Balance Sheet 60
Summary of Balance Sheet 60
Cash Flow Statement 62
Summary of Cash Flow Statement 62
Key Financial Ratio Analysis 64
CSL Limited – Ratio Charts 65
Activity Ratio Charts 65
Growth Ratios Charts 66
Leverage Ratio Charts 67
Liquidity Ratio Charts 67
Competing Players 69
Snapshot of Competing Players 70
AbbVie Inc 70
Key Company Facts 70
Company Description 70
AstraZeneca Plc 71
Key Company Facts 71
Company Description 71
Bayer Aktiengesellschaft (Bayer AG) 72
Key Company Facts 72
Company Description 72
Bristol-Myers Squibb Company 73
Key Company Facts 73
Company Description 73
GSK plc 74
Key Company Facts 74
Company Description 74
CSL Limited – In the News 75
14-Feb-2025 – European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE, the First Self-amplifying mRNA COVID-19 Vaccine 75
13-Feb-2025 – European Commission Approves CSL’s ANDEMBRY (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) 76
07-Feb-2025 – CSL Behring’s Gene Therapy HEMGENIX (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B 78
24-Jan-2025 – Australia’s Therapeutic Goods Administration (TGA) Approves Registration of CSL’s ANDEMBRY (garadacimab) for the Prevention of Recurrent Hereditary Angioedema (HAE) Attacks 80
13-Dec-2024 – CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE) 82
24-Oct-2024 – Investigations into lung cancer and into epigenetics recognised with 2 x $1.25 million CSL Centenary Fellowships 82
24-Apr-2024 – CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy 85
17-Apr-2024 – Mini brains and lab-on-a-chip wearables: Jumar Bioincubator officially begins its mission to build “Australia’s next CSL” 85
28-Mar-2024 – Vafseo approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients 88
19-Mar-2024 – Ferinject approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure 88
07-Mar-2024 – CSL Adopts Regional/National Public Health Timetable on the Removal of B/Yamagata Seasonal Influenza Virus Strain 90
23-Feb-2024 – CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy 90
11-Feb-2024 – CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human]) 92
05-Feb-2024 – New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster 92
16-Jan-2024 – Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options 95
15-Jan-2024 – Swissmedic Authorises CSL’s HEMGENIX (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B 97
03-Jan-2024 – CSL Behring Announces Availability of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe 99
CSL Limited – Key Deals 101
11-Jun-2024 – CSL Seqirus, a Proud Champion of Pandemic Preparedness, Signs an Agreement with the European Commission to Provide Pre-Pandemic Vaccines to the EU 101
01-May-2024 – CSL Seqirus and ARS Pharma sign agreement to commercialise neffy™ (adrenaline nasal spray) in Australia and New Zealand 102
12-Oct-2023 – CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites 104
04-Oct-2023 – Seven New CSL Global Research Acceleration Initiative Awardees Announced to Fast-Track Therapeutics Innovation 105
26-Sep-2023 – CSL Seqirus secures multi-year pandemic preparedness agreement as part of its continued partnership with the UK government 107
01-Mar-2023 – CSL Seqirus and Amarin sign licensing agreement to commercialise Vazkepa (icosapent ethyl) in Australia and New Zealand 109
12-Dec-2022 – CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics 110
01-Nov-2022 – CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology 112
26-Oct-2022 – CSL enters into Strategic Option and License Agreement with Translational Sciences 112
Appendix 114
Definitions 114
SWOT Analysis 114
PESTLE Analysis 114
Value Chain Analysis 114
ESG Spotlight 114
Financial Deep Dive 114
Financial Ratios – 115
Activity Ratios 115
Growth Ratios 116
Leverage Ratios 117
Liquidity Ratios 118
Market Ratios 119
Profitability Ratios 119
Research Methodology 120
Disclaimer 121
Contact Us 121

Tables

Table 1: CSL Limited – Company Facts
Table 2: CSL Limited – Digital Presence
Table 3: CSL Limited – Top Executives
Table 4: CSL Limited – Products
Table 5: CSL Limited – Services
Table 6: CSL Limited – Share Price Trend – Feb-2024 to Feb-2025
Table 7: CSL Limited – Ratio Analysis – 2021-2024
Table 8: CSL Limited – Competing Players
Table 9: Competing Players – AbbVie Inc – Key Company Facts
Table 10: Competing Players – AstraZeneca Plc – Key Company Facts
Table 11: Competing Players – Bayer Aktiengesellschaft (Bayer AG) – Key Company Facts
Table 12: Competing Players – Bristol-Myers Squibb Company – Key Company Facts
Table 13: Competing Players – GSK plc – Key Company Facts

Charts

Figure 1: CSL Limited- SWOT Analysis
Figure 2: CSL Limited – PESTLE Analysis
Figure 3: CSL Limited – Average Share Price Trend – Feb-2024 to Feb-2025
Figure 4: CSL Limited – Profit and Loss Statement – 2021-2024
Figure 5: CSL Limited – Balance Sheet – 2021-2024
Figure 6: CSL Limited – Cash Flow Statement 2021-2024
Figure 7: CSL Limited – Activity Ratio Charts
Figure 8: CSL Limited – Growth Ratio Charts (Value %)
Figure 9: CSL Limited – Leverage Ratio Charts
Figure 10: CSL Limited – Liquidity Ratio Charts